• Autonomous security robot (“ASR”) developer Knightscope is focused on a mission of making the United States more secure, particularly in the wake of some very recognizable national threats
• The company’s three ASR models help to secure the perimeter in business offices, government buildings, outdoor public venues and inside healthcare facilities
• The ASRs provide non-human capacity to avoid boredom on the job, be sickened by other people and suffer deadly injuries from violent criminals
• The unarmed sentinels are designed to identify, record and relay significant information to human personnel

Perimeter security is the first key to defending property integrity for nearly everyone, from private homeowners to corporate businesses, as well as for temporary event managers such as race directors and government military mobile command members. Perimeter defense in the form of the private security industry needs to be able to deal with a variety of challenges that may include trespassers from outside the infrastructure and employee inattention within the infrastructure. Autonomous Security Robot (“ASR”) developer Knightscope has built its mission and technological platform on what it sees as a need to improve how perimeter security is maintained within the United States. “We are on a mission to make the United States of America the safest country in the world. Yes, it is an audacious goal. But since when in our country do we shy away from what is hard and what is difficult? We are Americans,” a company video states (https://ibn.fm/k4RrK). The patriotic tone of the promotion underscores national concerns that came into clear focus 20 years ago when terrorists from other countries hijacked a handful of airplanes crossing American soil and turned them into weapons of terrible destruction that cost a large number of lives, and then when someone used the postal system immediately afterward to mail out letters tainted with a deadly biological pathogen to numerous people. More recently, similar concerns arose when political protests in the nation’s capital led to a riotous invasion of the halls of Congress in January, with threats against elected officials and a few deaths resulting from the incident. “Each (Knightscope robot) proudly displays the stars and stripes, signifying our patriotic duty to our country,” CEO William Santana Li says as he promotes the company’s mission to serve the United States in an investor relations video (https://ibn.fm/5To14). The company has introduced three models of ASRs thus far for patrolling indoor and outdoor locations. The company notes its robots are unsleeping “knights” that cannot be harmed by COVID or other human-borne viruses, or bored by lengthy periods of uneventful activity, or irreplaceably mortally wounded by malcontents. Knightscope’s ASRs also can come equipped with the ability for enhanced surveillance in total darkness using infrared and thermal cameras in tandem to observe and record activity that might not otherwise be visible (https://ibn.fm/Qdd4s). While the ASRs are not designed as armed mechanisms such as those portrayed as deadly AI machines in science fiction, or even as weaponized drones controlled by humans in military use, they are nevertheless useful in their AI-enhanced capacity of identifying people and select objects, such as license plates, and then alerting human controllers with recorded information as necessary. The ASRs have even been lauded after a heat-recognizing camera detected a spike in temperatures within a building and was able to summon intervention before a fire could create large-scale damage. Knightscope has topped 20,000 investors since rolling out its first autonomous product in 2015, utilizing a Reg A+ offering that allows Knightscope to attract private investments from both accredited and unaccredited investors (https://ibn.fm/04ZG5). For more information, visit the company’s website at www.Knightscope.com. Visit www.Knightscope.com/invest for a summary of Knightscope as an investment, with a blue Instant Messaging button for direct contact with their CEO. DISCLAIMER: You should read the Offering Circular and risks related to this offering before investing. This Reg A+ offering is made available through StartEngine Primary, LLC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. NOTE TO INVESTORS: The latest news and updates relating to Knightscope are available in the company’s newsroom at https://ibn.fm/Knight

• IAEA report notes that an adequate supply of uranium will be vital as nuclear power continues to provide an important source of the world’s carbon-free energy
• “Undiscovered resources must be converted to discoveries, which must then be developed in a timely matter,” report concludes
• UEC is focused on expanding uranium production while developing a pipeline of low-cost resources for major ongoing growth

A recent analysis of the world’s uranium supply by the International Atomic Energy Agency (“IAEA”) states that nuclear power will be a primary source of energy for the world in the coming years — assuming an adequate supply of uranium can be maintained (https://ibn.fm/ra0Vo). That report is great news for Uranium Energy (NYSE American: UEC), a U.S.-based uranium mining and exploration company that controls one of the country’s largest historical uranium exploration and development databases. UEC leverages this invaluable data to target and acquire properties that have been subject to exploration and development by senior energy firms in the past and that are ideally positioned to become major supplies of uranium in the coming years.

“Nuclear power is expected to be an important part of the worldwide energy mix at least through the next 50 years and by most projections well beyond,” the IAEA study reported. “That is, of course, provided an adequate supply of uranium is available to sustain the nominal growth rate for nuclear power of 1 to 3% per year that is projected by many analysts. The importance that a reliable supply will have on the future of nuclear power led the IAEA to undertake a study of uranium supply-demand relationships through 2050.”

The detailed report evaluates the adequacy of the world’s uranium supply to meet demand. The paper analyzes the supply of uranium given different levels of demand, ultimately concluding that “by 2025, primary supply sources are expected to cover 94% of requirements, and the role of Market-based Production is projected to grow from satisfying 45% of requirements in 2000 to 86% in 2025. Known resources are adequate to cover about 96% of Market-based Production requirements in the middle demand case. However, because of resource distribution and production capacity limitations, not all resources will have been depleted by 2050, leaving a cumulative deficit between production and requirements of nearly 850 000 t U. This deficit expands 3.5-fold in the high demand case. Even with the addition of undiscovered EAR-II, there will still be a deficit between production and Market-based Production requirements of about 307 000 t U in the middle demand case.

“The challenge for the uranium production industry will be to discover large, relatively low-cost deposits to fill the projected deficits,” the study concludes. “Plentiful secondary supply has depressed uranium market prices, which in turn has diminished incentive to undertake the exploration programmes needed to offset these deficits. . . . There is not a true shortage of potential resources. However, these undiscovered resources must be converted to discoveries, which must then be developed in a timely manner to ensure that their resources can be fully utilized to offset the projected deficits.”

UEC is focused on doing just that. The company’s mission — to expand uranium production using low-cost in-situ recovery (“ISR”) while developing a pipeline of resources for major ongoing growth — dovetails perfectly with the report from the IAEA noting the need for promising projects to be fully developed. The U.S. Geological Survey recently reported to the International Atomic Energy Agency that South Texas represents one of the world’s most prospective regions for new uranium discovery and development. Uranium Energy Corp has a strong presence in South Texas with the infrastructure in place to capitalize on the region for further exploration, development and production.

UEC discovered the Burke Hollow project in South Texas, and in a recent press release, their vice president of Resource Development stated, “…the extensive, lightly-explored trend extensions and remaining undrilled areas of the project have the potential to be the largest Goliad Formation deposit discovered to date in the South Texas Uranium Belt.” Uranium Energy Corp has the largest resource base of fully permitted projects in Texas and Wyoming of any U.S.-based producer.  The company is well positioned to supply the U.S. strategic Uranium Reserve as well as utility demand. UEC also has additional U.S. projects in their pipeline in New Mexico, Arizona, Colorado, and other projects in Canada and Paraguay. UEC is committed to providing low-cost, environmentally friendly uranium for the safe, highly reliable carbon-free energy that nuclear power provides.

For more information, visit the company’s website at www.UraniumEnergy.com.

NOTE TO INVESTORS: The latest news and updates relating to UEC are available in the company’s newsroom at https://ibn.fm/UEC

• BRSF signed MOU with leading provider of digital therapeutics for mental health sector to use data, AI to advance work in mental health disorders
• Company will provide proprietary NeuroCap, NeuroEEG devices to collect, transfer data from patients
• Collaboration could expand into a number of clinical and commercial applications

Brain Scientific (OTCQB: BRSF), a commercial-stage, health-care company developing products related to the brain including neurology, AI and machine learning, has signed a memorandum of understanding (“MoU”) with Ehave Inc. (OTC: EHVVF), a provider of digital therapeutics for the mental health sector (https://ibn.fm/ktiLG). The two companies aim to collaborate by using data and AI to correlate biomarkers to identify chronic pain, depression (major and persistent), PTSD, bipolar disorder, general anxiety, ADHD and schizophrenia. Brain Scientific and Ehave will team up to leverage graph-based AI and linked data protocols to develop neural net algorithms. These algorithms could be used to upload already trained neuronet into a specialized chip that Brain Scientific develops into a temporary e-tattoo or electrodes connected to the micro EEG positioned behind a patient’s ear. The brain e-tattoo is the BRSF’s new AI-powered, graphene-based solution that can process the signals from the sensors and wirelessly transfers data to a cloud application (https://ibn.fm/zcERv). Under the MOU, Brain Scientific would provide its proprietary data signal acquisition devices, NeuroCap(TM) and NeuroEEG(TM), for the Ehave platform. Ehave would integrate the devices to collect data from patients in real time and transfer that data into a cloud. NeuroCap is a patented, disposable EEG headset with 22 pre-gelled electrodes that anyone can set up in five minutes or less to record a patient’s brain activity. The cap is compatible with third-party amplifiers and the device also works with NeuroEEG, a proprietary portable, wireless, 16-channel amplifier that can easily be deployed across a broad spectrum of settings also requires minimal training. The devices allow for raw EEG data to be instantly transferred to a cloud, which enables remote access and interpretation by neurologists. These low-cost, portable and wireless devices provide the same quality of signal as conventional EEG devices and could be employed both in clinical and commercial settings. For example, one possible aspect of the collaboration could involve Ehave deploying NeuroCap and NeuroEEG in clinical settings with its partner healthcare providers such as psychiatrists, psychologists, psychotherapists and general practitioners. This would allow Ehave to collect the data representing electrophysiological changes in the brain before, during and after psychedelic drug administration. The MOU may also potentially lead to establishing or partnering with a lab that could be equipped with NeuroCap and NeuroEEG devices to conduct market studies to study consumer behavior and psychology in markets and capture data on different brain-related physiological and mental disorders. Likely to begin in Australia, this application could be rolled out in other locations where Ehave has a presence. The two collaborating companies will jointly own all data from any transactions arising from the MOU. Ehave will cover the testing and certification cost for products developed under the agreement and will receive full intellectual property rights, including the right to sell and distribute any such products, on a 50/50 split basis after all expenses, including research and development. To learn more about this company, visit www.BrainScientific.com/Invest-Now. NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF

• COVID-19 disease has shown propensity to affect patients’ long-term health by affecting cardiovascular and pulmonary systems
• Medical practitioners have increasingly turned towards ultrasound machines to scan critical organs while simultaneously limiting their exposure to potentially contagious patients
• Mediscan’s cloud-based ultrasound software allows medical professionals to accurately view and diagnose internal issues through 3D musculoskeletal, lung, cardiac imaging

COVID-19 has shown a propensity to affect an individual’s body in a number of different ways, including the long-term health of a patient’s cardiovascular and pulmonary system. As such, the need to properly diagnose lung infections, which could otherwise be sustained throughout a patient’s life, or myocarditis, an inflammation of the heart muscles which could go undiscovered if not properly diagnosed, has heightened the need for medical practitioners to make use of the proper technology to enable early diagnosis. Healthtech Solutions (OTC: HLTT), through its Mediscan Inc. subsidiary, has developed a cloud-based software for ultrasound technology which has proven to be highly effective in diagnosing internal organs potentially affected by COVID-19. Moreover, ultrasounds have also shown an ability to monitor a patient’s vital signs and single out any potential abnormalities. Ultrasound, a fast-evolving technology, can provide an immediate diagnosis of an internal issue in a patient’s body. When a symptomatic patient is suffering from COVID-19, bedside ultrasound is commonly used to scan critical organs, such as the heart, for damage (https://ibn.fm/BNrjM). Thus, ultrasounds can both avoid the need for patients to undergo potentially invasive physical examinations while simultaneously limiting the exposure to which medical practitioners may be subjected when dealing with the individual. Mediscan’s technology has shown great success in musculoskeletal (“MSK”), lung and cardiac imaging, enabling rapid pathology evaluation. Scanning the lung or the MSK sub-system, Mediscan directly images the target area being checked, saves it as a reference, and then automatically compares it to previous images. This enables it to determine the changes in a patient’s condition. In addition to its utility in MSK, lung and cardiac imaging, the use of portable ultrasounds equipped with Mediscan’s cloud-based software application provides healthcare providers with a flexible and easy-to-use solution through which to accurately evaluate, triage and diagnose COVID-19’s effects on contagious patients in isolation. This is particularly useful in situations where traditional MRI’s, CET or PET scans are otherwise not accessible. Traditional ultrasound technology has long relied on producing 2D-grayscale images, which Mediscan’s technology can transform into a digital 3D-HD format. Once an image has been captured in 2D, Mediscan’s software can convert it using its proprietary cloud-based software application process, providing medical professionals with 3D medical images of different organs, including the heart, lungs, tendons, skin and nerves. COVID-19 can vary in the way it affects the body, ranging from mild and negligible symptoms to much more life-threatening forms. However, in all cases, it is necessary to diagnose each patient and search for potential pulmonary or cardiac damage as a priority. An early diagnosis can play a critical role in ensuring a patient’s full recovery, with technologies like ultrasounds playing an increasingly important role. The widening scope of clinical applications for Mediscan’s ultrasound-based technology as well as its growing potential to serve as an early diagnosis tool for coronavirus-linked organ damage has further boosted the company’s growth prospects within the North American medical imaging market, an industry which boasted an addressable target market size of $134 billion as of 2020 (https://ibn.fm/TSPAW). For more information, visit the company’s website at www.MyMediScan.com. NOTE TO INVESTORS: The latest news and updates relating to HLTT are available in the company’s newsroom at https://ibn.fm/HLTT

• Pandemic has increased incidence of stress-induced symptoms such as insomnia and headaches
• Demand for products focused on relieving these symptoms has soared
• SHRG quick to move, address this growing market need with release of relaxing, stress-relieving, sleep-promoting beverage

It has long been known that stress can wreak havoc on people’s health and general sense of well-being, and the pandemic has confirmed that as people of in previous good health have reporting a host of seemingly unrelated symptoms, including intense headaches, insomnia and hair loss — for which chronic stress was often the only culprit, states a recent NPR article (https://ibn.fm/Za9f1). Recognizing the growing market needs for products that can help relieve stress, Sharing Services Global (OTCQB: SHRG), a publicly traded  holding company specializing in the health and wellness direct-selling industry, offers a powerful beverage product called Unwined(TM) — a relaxing, stress-relieving, sleep-promoting beverage that may help with immune support. A growing body of research shows that high stress levels over a longer period can significantly change physical health and affect nearly the whole body. Insomnia is one of the most common symptoms with increasing incidence during the pandemic. The article cites Express Scripts, a major pharmacy benefit manager, which reports that prescriptions for anti-insomnia medications rose by 15% early in the pandemic. Hormones are at the center of this complex play as the body keeps pumping out stress hormones until it tires itself out, leading to a whole host of unwanted symptoms, including insomnia. To address the increasing needs of its consumer and distributors, the company’s wholly owned subsidiary known as Elepreneurs US, LLC, and Elevacity(R) U.S. LLC, released a new product: Unwined, a beverage created to provide relaxing, stress-relieving, sleep-promoting benefits that may help with immune support. Made with a blend of ingredients such as antioxidants, adaptogens, extracts and minerals formulated to help reduce excess stress hormones such as cortisol and promote relaxation and sleep, Unwined is an ideal complement to Elevacity’s already existing products. The product line is designed to offer consumers a safe and efficient offering to help elevate their lives without the use of additives or fillers. Focused on elevating health, wealth and happiness through proprietary powerful nutritional products, SHRG appears to prove again that it understands the key industry trends as they emerge. With this wellness beverage as the new addition to its brand portfolio, SHRG continues to position itself as a direct selling company in the wellness space, quick to move as market needs evolve to offer consumers and independent contractors alike solutions that help them live healthier elevated lives. For more information, visit the company’s websites at www.SHRGInc.com, www.Elevacity.com, or www.Elepreneur.com. NOTE TO INVESTORS: The latest news and updates relating to SHRG are available in the company’s newsroom at http://ibn.fm/SHRG

• Data, not time, is now a company’s most valuable asset
• Investing in analytics leads to a host of benefits, including higher growth
• SRAX’s innovative Sequire technology unlocks stock buyers’ behaviors, trends for issuers of publicly traded companies

Today, businesses need every piece of leverage available in order to compete and maximize corporate efficiencies. Efficiency is underscored by ranking and managing resources—a task that can be a moving target based on trends. Seven years ago, Harvard Business Review made the case that time was a company’s most valuable commodity. In 2017, The Economist contested that data was the world’s – not just a company’s – most valuable asset (https://ibn.fm/d8Asv). The Economist isn’t wrong, as capitalizing on data insights and analytics can save time and, ultimately, make or break a company, according to Forbes’ Insight Team. To that point, digital marketing and data management technology company SRAX (NASDAQ: SRAX) offers a product lineup that, amongst other things, helps companies realize and harness the value of data built into their business. Consumers are increasingly becoming aware of the value of their data, wanting it to remain private and expecting compensation if it is released. These demands have social media platforms facing backlash from users, as well as growing regulatory scrutiny about marketing used to bait consumers. For its part, SRAX is positioned on the leading edge, building a trusted, opted-in consumer data set that companies can benefit from in multiple ways. In the Forbes piece titled, “6 Reasons Why Investment in Analytics Is Essential,” the authors lay out a cogent case to not delay making investments in analytics to improve the top and bottom line. Rationale to benefits of comprehensive analytics include building a stronger competitive position, identifying new business opportunities and emerging trends, uncovering ways to reduce expenses, detecting production and service problems sooner; getting a deeper understanding of customers and achieving higher growth. SRAX offers public companies a comprehensive platform, branded “Sequire,” to see data sets derived from the platform’s more than 3 million active users, consisting of investors and traders from 90+ public companies (https://ibn.fm/wd8Hw). The innovative platform is expanding its analytical prowess, as its accelerating growth means more data, which leads to more users, and so on. Sequire provides its clients valuable insight on behaviors of shareholders and market makers, an easy way to measure ROI on spend with investor relations programs and corporate communications strategies, in addition to combining verified and historical shareholder data to target relevant investors across different channels. Speaking to the growth and value proposition, Chris Lahiji, founder of LD Micro, the pre-eminent event platform for emerging companies, recently said he sees Sequire as a path to importance akin to an industry business information giant. “One day executives will rely on Sequire the same way investors rely on Bloomberg,” said Lahiji in a conversation on Sequire’s ability to deliver actionable insights on investor activity (https://ibn.fm/hUQvN). That’s a lofty goal, but one not out of reach when considered in context with the benefits laid out by Forbes. For more information, visit the company’s website at www.SRAX.com. NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://ibn.fm/SRAX

• The 100% growth reflects the company’s attention to metrics and feedback to continuously improve its platform and optimize available services and options
• Fan Pass is holding exclusive contests for artists on their platform, including high-value prizes for the most engagement
• Fan Pass Pro Services offers artists access to merchandising and marketing services they may not have access to otherwise
• The global music streaming market is expected to grow consistently over the next few years and reach $76.9 billion in 2027, from $20.9 billion in 2019

For the second month in a row, mobile technology and marketing company Friendable (OTC: FDBL) reported exponential growth of its Fan Pass platform, an application designed to connect fans with their favorite artists through streaming events and pay-per-view exclusives for a fraction of the cost of attending in person.

The company’s second application platform following friendship and dating app Friendable, Fan Pass was launched in July 2020, during the COVID-19 pandemic. From December 2020 to January 2021, the company made record gains in artist sign-ups. In February 2021, Fan Pass reported streaming event growth of 100%, an increase that provides a glimpse into how Friendable is building upon milestone achievements, trends and feedback from fans and artists alike.

“Metrics mean everything, no matter whether they’ve increased or decreased, and they continue to guide our team on the journey toward success on every level. Metrics allow our team to make informed adjustments based on the results of a particular initiative, feature, contest, or revenue event,” CEO Robert A Rositano Jr. said, explaining the platform’s growth (https://ibn.fm/3vrna).

Going into March, the Fan Pass Instagram page (@fanpasslive) announced an exclusive March Artist Contest to further engage its target audience and increase its own visibility and reach. The contest’s premise is for artists to compete for the most live stream viewers during the month. Prizes available in the contest include:

• 1st Place: A GoPro HERO9 (5K video, 20MP, and more) or $300 in cash
• 2nd Place: Streaming Kit ($250 value) or $150 in cash
• 3rd Place: Custom Design ($100 value) or $50 in cash
• BONUS: The first 50 artists to schedule, promote, and complete a live event in March win $50

Via the platform, fans can stay connected with their favorite Fan Pass artists through two subscription options. For only $3.99 a month ($38.30 annually), fans get an all-access experience that includes:

• Live performances and online performances (including exclusive pricing for pay-per-view events)
• Backstage exclusives before, during, and after the show or event
• Livestreaming studio sessions
• Behind-the-scenes footage of music video and photoshoots
• Special interviews and one-on-one videos
• Daily life highlight streams for the artist

Additionally, merchandise is available through the Fan Pass website, and fans have the possibility of getting exclusive merchandise from the artists on the platform or to support the purchase of exclusive Fan Pass Gear.

Artists can sign up for the platform for free but have the option of using the Fan Pass Pro Services at an additional cost, ranging from $45 to $500, and including different tiers of marketing materials, logo design and merchandise design services. The Fan Pass Pro Services make it possible for artists to create their merchandise and focus on marketing strategies at an affordable price while starting on the platform and in the industry (https://ibn.fm/DeaaI).

Before the pandemic, the global music streaming market was valued at $20.9 billion in 2019. The market is expected to expand at a CAGR of 17.8% from 2020 to 2027, to reach an anticipated $76.9 billion (https://ibn.fm/XqU2K). Streaming concerts have become an innovative way to circumvent the restrictions placed on in-person concerts due to the pandemic. Friendable is in a unique position to disrupt the industry with its all-inclusive VIP artist and fan experience that enables artists to continue engaging with fans around the world and earning revenue while doing so.

For more information, visit the company’s websites at www.Friendable.com or www.FanPassLive.com.

NOTE TO INVESTORS: The latest news and updates relating to FDBL are available in the company’s newsroom at http://ibn.fm/FDBL

• Cancer screenings, treatments declined during COVID-19 pandemic, highlighting need for personalized therapies to improve outcomes
• Comprehensive genomic, transcriptomic sequencing of patient samples complete, patient outcome data obtained from UPMC-Magee
• Project is template for future partnerships with other healthcare institutions to expand POAI’s AI-driven clinical models to other cancers

The consequences of COVID-19 sent shock waves throughout the healthcare sector in more ways than just the direct impact of coronavirus infections. A recent study (https://ibn.fm/6LLiW) showed that cancer screenings and treatments declined during the pandemic, with the authors cautioning that the fallout could be dramatic. The study’s results certainly highlight the need for more individualized treatment regimens that improve patient outcomes, minimize patient visits and help patients with advanced disease at the time of treatment. This is the area of specialty of Predictive Oncology (NASDAQ: POAI), a knowledge-driven medicine company that focuses on applying data and artificial intelligence (“AI”) to cancer personalized medicine and drug discovery. Through its Helomics division, the Minneapolis-based company has just made a significant stride in its efforts to build AI-driven models of ovarian cancer by completing key data generation milestones in a retrospective study in collaboration with UPMC-Magee Women Hospital, an affiliate of the University of Pittsburgh Schools of the Health Sciences (https://ibn.fm/KSr2G).

While the science and technology are complex, the overarching concept isn’t: Test drugs on individual tumors in a lab setting to better inform doctors’ decisions in the real world. Effectively, Helomics performs chemotherapy on a patient’s tumor before the patient gets the drug to provide the oncologist with information on what may or may not work before the oncologist ultimately prescribes a treatment plan.

During more than 15 years of clinical testing, Helomics has amassed a proprietary knowledge base, coined TumorSpace(TM), of more than 150,000 tumor drug response profiles. Simply, Helomics grows patient tumors and tests how they respond to drugs, constantly analyzing and collating data as it builds multi-omic predictive models of tumor drug response and outcome. “Multi-omic”—biotech speak for integrating data collected from different omic levels (meaning things like genomes, proteome, etc.) to understand interactions and influence on disease pathogenesis—involves using cutting-edge machine learning technology to combine a drug response profile with a genomic profile to deliver a more meaningful and effective impact than genomics alone could.

Helomics currently provides treatment option recommendations to personalize therapy based on tumor profiles as it continues development of its AI-driven models. Once the AI models are complete and validated, it will move exclusively to the AI-driven computer models.

As it happens, looking back is often the best way to move forward. That was the purpose of the study with UPMC-Magee Women Hospital. Comprehensive genomic and transcriptomic sequencing of patient samples is now complete, and patient outcome data has been obtained from UPMC-Magee. These data will now be used to drive POAI’s AI models of ovarian cancer and their internal ovarian cancer drug re-purposing project.

“The successful generation of high-quality genomic and transcriptomic data from archived materials at Helomics, together with the gathering of historical outcome data from our collaborator UPMC-Magee, demonstrates that we can leverage Helomics’ unique asset and deliver significant value,” said Predictive Oncology CEO Dr. Carl Schwartz. “Furthermore, this project is a template we can use to partner with other healthcare institutions and expand our AI-driven clinical models to other cancers.”

According to the American Cancer Society, about 21,410 women will receive a new diagnosis of ovarian cancer this year and approximately 13,770 women will die from the disease.

POAI is bringing precision medicine, or tailored medical treatment using the individual characteristics of each patient, to the treatment of cancer. Through its Helomics division, the company leverages its unique, clinically validated patient derived (“PDx”) smart tumor profiling platform to provide oncologists with a roadmap to help individualize therapy. In addition, the company is leveraging artificial intelligence and its proprietary database of over 150,000 cancer cases tumors to build AI-driven models of tumor drug response to improve outcomes for the patients of today and tomorrow.

For more information, visit the company’s website at www.Predictive-Oncology.com.

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

• Cybin’s latest offering generated exceptional demand; announces upsize of “bought deal” offering
• Burgeoning psychedelic sector attracts investors’ attention as compound may prove effective in mental health treatments.
• Cybin appears set for rapid growth as research accelerates, public acceptance grows.

Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotech company focused on psychedelic therapeutics for various psychiatric and neurological conditions, has announced that it has upsized the terms of its “bought deal” offering due to strong demand. The deal size, previously announced at CDN$20,025,000, has increased to aggregate gross proceeds of CDN$30,015,000 as the underwriters have agreed to purchase 13,340,000 units of the company at CDN$2.25 per unit. Cybin intends to use the net proceeds to further develop its clinical trials, novel molecule programs and technologies enhancing the patient experience as well as for working capital and general corporate purposes.

The announced upsize comes against the backdrop of a growing demand for psychedelic companies. The burgeoning sector is attracting increasing attention from investors with more companies going public and rapidly increased research sparking greater public acceptance and potential decriminalization (https://ibn.fm/RS6Y1). The stigma around the compound has started to wane as recent studies point towards the potential use of psilocybin, which is found in “magic” mushrooms, for treating patients suffering from mental health diseases such as depression, anxiety and PTSD.

More and more academic institutions, including those with a world-class reputation such as Johns Hopkins and Imperial College London, are establishing specialized programs to further investigate the role psilocybin could play in the mental health space, especially in alleviating symptoms of major depression. In the past, criminalization and the stigma attached to the compound have hindered researchers from exploring the medical benefits of psilocybin and other psychedelics. More recently, however, the push to remove the barriers to research has been gaining momentum.

Cybin is committed to developing novel therapeutics, delivery methods and treatment regimens based on psychedelic compounds such as psilocybin, DMT, MDMA and other analogues to potentially treat neurological disorders. The company is working to become the first company to bring a psilocybin drug to market targeting major depressive disorder addressing a vast potential market with an estimated 17 million people in the United States and 300 million people worldwide experience depression (https://ibn.fm/Tn0bb). As a company developing psychedelic therapeutics for psychiatric and neurological conditions and with a strong executive medical and research team that boasts extensive experience in the field, Cybin appears well-positioned within the thriving sector that is set for rapid growth as research accelerates and public acceptance grows.

For more information, visit the company’s website at www.Cybin.com.

NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN

• Nextech AR Solutions Corp. is a leading provider of web-based augmented reality for e-commerce, advertising and virtual events
• The company provides businesses with a powerful end-to-end augmented reality platform designed specifically to increase online sales
• Nextech AR’s current customer base includes the likes of Amazon, Johnson & Johnson, ViacomCBS, Toyota and Carnegie Mellon University
• The company achieved record bookings in Q4 2020 of $7.3 million (estimated), marking a greater than 275% year-over-year increase
• The Nextech AR management team has extensive experience stemming from time with a collection of Fortune 500 companies

Nextech AR Solutions (CSE: NTAR) (OTCQB: NEXCF), based in Vancouver, Canada, is a leading provider of web-based augmented reality for e-commerce, advertising and virtual events, with technology ranging from simple 3D images to using 360-degree videos. Nextech AR provides businesses with a powerful end-to-end augmented reality platform designed specifically to increase online sales. The company is currently pursuing four unique verticals with its innovative technology, including:

• Virtual Conference Platform: Nextech’s advanced Augmented Reality and Video Learning Experience Platform for Events leverages an SaaS model to give organizations the ability to create engaging virtual event management and learning experiences. Automated closed captions and translations for over 64 languages are available. The global virtual events market was valued at $90 billion in 2020 by Grandview Research, and it’s expected to reach more than $400 billion by 2027.
• ARitize(TM) for eCommerce: Launched in early 2019, the company’s SaaS platform for webAR in eCommerce serves as a ‘full funnel’ end-to-end e-commerce solution for the AR industry. The solution includes the Aritize360 app for 3D product capture, ‘Try it On’ technology for online apparel, 3D and 360-degree product views, ‘one click buy’ and much more.
• ARitize(TM) 3D/AR Advertising Platform: Launched in Q1 2020, this ad platform is being marketed as the industry’s first end-to-end solution leveraging 3D asset creation for 3D/AR ads. In 2019, according to IDC, global advertising spend totaled roughly $725 billion.
• ARitize(TM) Hollywood Studios: The studio is in development as a means of producing immersive content using 360-degree videos and augmented reality as primary display platforms.

Unique Marketing Strategy Nextech AR’s efforts to disrupt the market for web-based augmented reality for e-commerce are supported by a unique go to market strategy. First, the company seeks to build or acquire platforms targeting a number of rapid growth industries, most notably AR, edTech, e-commerce, 3D/AR advertising and virtual & hybrid events. After identifying these market opportunities, the company seeks to integrate new AR technologies into existing or novel platforms in an effort to secure market share and promote growth. These technologies include WebAR, Human Holograms, 360 Portals, ScreenAR, Genie in the bottle and AiRShow. Nextech AR then aims to leverage these platforms to land and expand partnerships with a number of blue chip customers. The company’s current customer base includes the likes of Amazon, Johnson & Johnson, ViacomCBS, Toyota and Carnegie Mellon University. Growth Capital Nextech AR generates revenue through a software-as-a-service model from technology services, delivery of service revenue and sales of products through e-commerce. As noted in its latest investor presentation, the company achieved record bookings in Q4 2020 of $7.3 million (estimated), marking a greater than 275% year-over-year increase. The company also realized greater than 235% revenue growth for calendar 2020, reporting $20 million for the 12-month period. Nextech AR attributes its 2020 increase in revenues to the contracts secured with new customers, expanded agreements with existing customers and additional conversions from e-commerce channels. With its newly launched 3D ad network now bolstering its operations, Nextech AR is projecting revenues in excess of $50 million for 2021. Recent Company Highlights

• February 16, 2021: The company announced it has hired Zak Mcleod, formerly of Fastly, as its new Senior Director of Sales – EMEA. The company also announced that Rory Ganness, formerly of Salesforce.com, has joined the Nextech team as Director of Enterprise Sales – North America.
• February 11, 2021: The company announced the launch of version 2.0 of its AiR Show app, an application that turns top music artists into interactive ‘live’ holograms, providing an immersive and engaging AR experience.
• February 8, 2021: The company announced the launch of new standardized chat features within its Virtual Experience Platform (“VXP”) and recently-launched ARoom collaborative streaming solution. Nextech will also offer the chat platform as a stand-alone SaaS service externally, increasing the company’s revenue potential for 2021.
• January 26, 2021: The company announced, in partnership with ARB Meetings and Events, it has signed a six-figure annual contract to supply its InfernoAR video conferencing and virtual events platform to NAMD.
• January 25, 2021: The company announced that Strategic Site Selection (“SSS”), a 15 year old site selection leader in the meeting and events industry, has selected Nextech AR as a preferred channel partner, making Nextech’s industry leading virtual experience platform and services available to SSS clients.
• January 20, 2021: The company announced that Microsoft’s Azure Cloud Services platform will be a standard offering across its virtual experience platforms and consumer apps, enabling hyper-scalable, secure and immersive events and applications for users.
• January 15, 2021: The company signed a renewal agreement with Poly with an initial value of $470,000 for a six-month term and the potential for additional revenue after the six months.

Management Team Evan Gappelberg is CEO and Founder of Nextech AR. He is an experienced operating executive specializing in creating, funding and running hyper-growth startups in both the public and private sectors. Notably, he took Take-Two Interactive Software Inc. (NASDAQ: TTWO) public with a market cap of $30 million and played a key role in guiding its growth to a current market cap of roughly $14 billion. Mr. Gappelberg has extensive experience as both a hands-on operating executive and a public markets professional. Paul Duffy is the company’s President. He is a serial entrepreneur with over 25 years of experience in successfully starting, expanding, diversifying and selling global technology companies. Mr. Duffy is the creator of the HumaGram and inventor of the patent for Holographic Telepresence over the Internet (“TOIP”). Augen Winschel is the COO of Nextech AR. He is an 18-year SAP executive with over 20 years of leadership experience in the areas of business management, business operations, marketing, product management, digital business and enterprise artificial intelligence. Kashif Malik, CPA, CA, is the company’s CFO. He has over 15 years of financial experience spanning IPOs, M&A activity, corporate restructuring and capital raising. Mr. Malik has worked globally with public and private companies, including Merck & Company Inc. (NYSE: MRK), Real Matters Inc. (TSX: REAL) and Constellation Software Inc. (TSX: CSU). He obtained his Chartered Accountant designation while working at Deloitte. Hareesh Acchi is the company’s President of 3D/AR Advertising. He is a 20-year Microsoft technology veteran with experience leading digital transformation and scaling businesses and enterprise organizations across the advertising industry. For more information, visit the company’s website at www.NextechAR.com. NOTE TO INVESTORS: The latest news and updates relating to NEXCF are available in the company’s newsroom at https://ibn.fm/NEXCF